Publication:
Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic

Simple item page
dc.contributor.authorÜNDER, DUYGU
dc.contributor.authorENVER, CÜNEYD
dc.contributor.authorDEMİRCİ, MUHAMMED YASİR
dc.contributor.authorAYHAN, YUNUS EMRE
dc.contributor.authorÖZGAN, BETÜL
dc.contributor.authorİLERLER, ENES EMİR
dc.contributor.authorOKUYAN, BETÜL
dc.contributor.authorERTÜRK ŞENGEL, BUKET
dc.contributor.authorKOCAKAYA, DERYA
dc.contributor.authorSİLİ, ULUHAN
dc.contributor.authorTİGEN, ELİF
dc.contributor.authorKARAKURT, SAİT
dc.contributor.authorKORTEN, VOLKAN
dc.contributor.authorSANCAR, MESUT
dc.contributor.authorsÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.
dc.date.accessioned2024-06-26T13:04:16Z
dc.date.available2024-06-26T13:04:16Z
dc.date.issued2024-01-01
dc.description.abstractObjectives: Drug-related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist-led medication review in hospitalized probable patients with coronavirus disease-2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in Türkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician’s acceptance rate of clinical pharmacists’ recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug-related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.
dc.identifier.citationÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al., "Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic", Turkish Journal of Pharmaceutical Sciences, cilt.21, sa.2, ss.152-158, 2024
dc.identifier.doi10.4274/tjps.galenos.2023.47105
dc.identifier.endpage158
dc.identifier.issn1304-530X
dc.identifier.issue2
dc.identifier.startpage152
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85195141012&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/297098
dc.identifier.volume21
dc.language.isoeng
dc.relation.ispartofTurkish Journal of Pharmaceutical Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectYaşam Bilimleri
dc.subjectBiyoteknoloji
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectLife Sciences
dc.subjectBiotechnology
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectMikrobiyoloji
dc.subjectTROPİKAL TIP
dc.subjectBİYOTEKNOLOJİ VE UYGULAMALI MİKROBİYOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectLife Sciences (LIFE)
dc.subjectCLINICAL MEDICINE
dc.subjectMICROBIOLOGY
dc.subjectTROPICAL MEDICINE
dc.subjectBIOTECHNOLOGY & APPLIED MICROBIOLOGY
dc.subjectMoleküler Tıp
dc.subjectFarmasötik bilim
dc.subjectMolecular Medicine
dc.subjectPharmaceutical Science
dc.subjectclinical pharmacist
dc.subjectCOVID-19
dc.subjectdrug-related problem
dc.subjectmedication review
dc.subjectPCNE
dc.titleClinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic
dc.typearticle
dspace.entity.typePublication
local.avesis.iddd5be7d1-0312-4241-b183-51a246927bcc
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication1f7ee0d9-97e4-47f7-87c9-3d6edf0c391b
relation.isAuthorOfPublicationfb414cc8-20a1-4d7c-8c51-06b95dc3a551
relation.isAuthorOfPublicationccf59216-2ab4-487a-a235-659ba2406470
relation.isAuthorOfPublication19ea3709-6289-4cd7-8b16-c61c85137f7c
relation.isAuthorOfPublicationd1518cbd-d389-4ab5-a1b6-7ac1d99621df
relation.isAuthorOfPublication8c11983e-1013-4342-98e6-f607e2ed43a6
relation.isAuthorOfPublicationf6e7969a-ea61-403f-8772-1a8478556223
relation.isAuthorOfPublication67d5b9df-08b7-4c37-b042-45ea89a4c23d
relation.isAuthorOfPublication2771cdd6-7c3b-45a8-89fe-a429a2950516
relation.isAuthorOfPublicatione62a1e57-9a52-4268-a049-905daa202980
relation.isAuthorOfPublicationfad8e847-d87e-49b7-ad74-3ff14b50ed24
relation.isAuthorOfPublicationbe661872-e895-4271-a0b7-82c5368ec000
relation.isAuthorOfPublication27f6afa3-0e46-45c9-a302-a6493c69bffb
relation.isAuthorOfPublication87a6fc65-406c-478f-bc6d-ffaaaf1f7b31
relation.isAuthorOfPublication.latestForDiscovery1f7ee0d9-97e4-47f7-87c9-3d6edf0c391b

Files

Collections

Research Outputs